Chenxi Yan

Dr. Chenxi Yan


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2025 in Cellular Oncology
Verified
Journal Article
Open access
PDF file
CYChenxi Yan
Chenxi Yan
YCYanjie Chen
Yanjie Chen
YTYitao Tian
Yitao Tian
SHShaojie Hu
Shaojie Hu
HWHeng Wang
Heng Wang
WSWei Sun
Wei Sun
Lung cancer remains the leading cause of cancer-related mortality worldwide, with limited treatment efficacy and frequent resistance to conventional therapies. Recent advances have uncovered the critical influence of the human microbiota—complex communities of bacteria, viruses, fungi, and other microorganisms—on lung cancer pathogenesis and therapeutic responses. This review synthesizes current knowledge on the compositional and functional roles of microbiota across multiple body sites, including the gut, lung, tumor microenvironment, circulation, and oral cavity, highlighting their contributions to tumor initiation, progression, metastasis, and immune regulation. We emphasize the bidirectional communication between microbial metabolites and host immune pathways, particularly the gut–lung axis, which modulates systemic and local antitumor immunity. Importantly, microbiota composition has been linked to differential responses and toxicities in chemotherapy, radiotherapy, targeted therapy, and immune checkpoint blockade. Microbiota-targeted interventions, such as probiotics, fecal microbiota transplantation, and selective antibiotics, show promising potential to enhance treatment efficacy and mitigate adverse effects. However, challenges remain in clinical translation due to interindividual microbiome variability, mechanistic complexities, and limited longitudinal data. Future research integrating multi-omics, microbial functional profiling, and controlled clinical trials is essential to harness the microbiome as a precision medicine tool in lung cancer management. This review provides a comprehensive overview of the emerging role of microbiota in lung cancer development and therapy, offering new perspectives for innovative therapeutic strategies.

1 January 2026 in Cardiology Research and Practice
Verified
Journal Article
Open access
XZXiaoxue Zhang
Xiaoxue Zhang
CYChenxi Yan
Chenxi Yan
SLShiliang Li
Shiliang Li
CCCai Cheng
Cai Cheng
Background: Transcatheter aortic valve replacement (TAVR) has been established as an alternative to surgery for high‐risk aortic regurgitation (AR) patients. However, its applicability to low‐ and intermediate‐risk populations remains under investigation. This study evaluates the clinical outcomes, quality of care, and patient‐centered implications of TAVR versus surgical aortic valve replacement (SAVR) in this population. Methods: Between 2021 and 2024, clinical data were retrospectively analyzed from 70 AR patients at our center, including 37 who underwent TAVR and 33 who received SAVR with bioprosthetic valves. Baseline characteristics, perioperative metrics, and major clinical outcomes were assessed. International registry data (FRANCE‐TAVI and ALIGN‐AR) were utilized for external validity comparisons. Results: Baseline characteristics were comparable between groups. TAVR was associated with shorter operation time ( p = 0.001), reduced blood use ( p < 0.001), and shorter hospital stays ( p = 0.021). No 30‐day mortality was observed in TAVR, whereas four deaths occurred in the SAVR group ( p = 0.029). Conduction abnormalities differed, with complete left bundle branch block (CLBBB) more frequent in TAVR ( p = 0.025) and complete right bundle branch block (CRBBB) in SAVR ( p = 0.029). Despite its minimally invasive nature, ICU observation time remained similar ( p = 0.339) due to perioperative complications. Economic analysis suggests potential cost savings with TAVR in specific scenarios. Conclusion: TAVR offers favorable short‐term outcomes for low‐ to intermediate‐risk AR patients, yet challenges in perioperative care require optimization. Long‐term studies and multicenter trials are needed to refine patient selection and postprocedural management strategies.

1 August 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
CYChenxi Yan
Chenxi Yan
SHShaojie Hu
Shaojie Hu
YTYitao Tian
Yitao Tian
XZXiaoxue Zhang
Xiaoxue Zhang
WSWei Sun
Wei Sun
Background: Distinguishing multiple primary lung adenocarcinomas (MPLAs) from intrapulmonary metastases (IPMs) is essential for accurate staging and treatment planning. However, existing histologic and molecular criteria remain limited in diagnostic accuracy. Spread through air spaces (STAS) has been recognized as a marker of tumor aggressiveness, but its role in differentiating MPLA from IPM remains unclear. This study aimed to assess whether STAS can serve as a supportive marker to differentiate IPM from MPLA under both histologic and molecular frameworks. Methods: We retrospectively enrolled 170 patients who were preoperatively diagnosed with MPLA and underwent surgical resection of multiple lung lesions. Clinical, histopathologic, and molecular data—including broad-panel next-generation sequencing (NGS) results [e.g., epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), tumor protein p53 (TP53), among others]—were collected. Tumors were classified as MPLA or IPM using histologic criteria alone and a combined histologic-molecular algorithm. The presence and quantity of STAS were evaluated and analyzed as potential predictors of IPM. Results: STAS was more frequent in the IPM group across both classification methods and was an independent predictor of IPM. Driver gene mutations (e.g., EGFR, KRAS) differed significantly between MPLA and IPM. The 83.5% concordance between histologic and combined classifications suggests potential bias in histology alone. In resource-limited settings, STAS may offer a cost-effective adjunct to support IPM diagnosis when molecular data are unavailable. Conclusions: STAS is associated with IPM and may serve as a supportive diagnostic marker when distinguishing IPM from MPLA. In resource-limited settings where molecular testing is not always available, STAS may offer a practical, cost-effective histologic adjunct to guide clinical decision-making.

27 July 2026 in Clinical and Translational Medicine
Verified
Journal Article
Open access
YCYanjie Chen
Yanjie Chen
HWHeng Wang
Heng Wang
XTXimin Tan
Ximin Tan
CYChenxi Yan
Chenxi Yan
FLFangfang Liu
Fangfang Liu
QCQian Chu
Qian Chu
Background: Non‐small cell lung cancer (NSCLC) remains a leading cause of global cancer mortality. Increasing evidence implicates aberrant cholesterol metabolic reprogramming as a key facilitator of tumour malignancy; however, the mechanistic connections between lipoprotein metabolism and NSCLC pathogenesis remain elusive. Here, we investigate the unrecognised oncogenic role of cholesteryl ester transfer protein (CETP), a central lipid exchange mediator. Methods: Serum lipid profiles from 151 NSCLC patients were analysed, and CETP mRNA expression level was evaluated in normal lung ( n = 47) and NSCLC tissue ( n = 54) and paired NSCLC tissue microarrays ( n = 113). Integrated ChIP‐seq/RNA‐seq analyses, ChIP–qPCR, dual‐luciferase reporter and ubiquitination assays were performed to investigate CTBP1‐mediated CETP transcription. Functional studies in NSCLC cells, xenograft models and eight patient‐derived organoids evaluated the role of the CTBP1–CETP axis in lipid remodelling, ferroptosis and the therapeutic efficacy of obicetrapib alone or combined with RSL3. Results: CETP was significantly up‐regulated in NSCLC tissues and predicted poor overall survival in both LUAD (HR = 1.46, 95% CI 1.13–1.87, p = .0033) and LUSC (HR = 1.51, 95% CI 1.12–2.01, p = .0067). CTBP1 activated CETP transcription, and CTBP1 ubiquitination further enhanced its transcriptional activity. The CTBP1–CETP axis promoted ferroptosis resistance by lipid accumulation. Obicetrapib phenocopied CETP depletion and synergised with RSL3 to inhibit tumour growth in NSCLC cells, xenografts and patient‐derived organoids. Conclusions: Our study delineates a novel CTBP1–CETP–lipid droplet–MAPK signalling cascade that couples metabolic rewiring with ferroptosis evasion. These insights establish the CTBP1–CETP axis as a critical cell fate determinant, positioning pharmacological CETP inhibition (e.g., obicetrapib) as a translatable therapeutic vulnerability in lipid‐dependent, ferroptosis‐resistant NSCLC.